Pregnancy and antiphospholipid syndrome;Syndrome des antiphospholipides et grossesse

Revue de Medecine Interne

Volumn 32, Issue SUPPL. 1, 2011, Pages

  Arnaud, L ^a,b   Mathian, A ^a,b,c   Le Thi Huong, D ^a   Costedoat Chalumeau, N ^a,c   Amoura, Z ^a,b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Antiphospholipid syndrome; Pregnancy

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; PREGNANCY;

ABORTION, HABITUAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FEMALE; FETAL DEATH; HUMANS; PREGNANCY;

EID: 79956264631     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2011.02.012     Document Type: Article

References (63)

1. Asherson R.A., Khamashta M.A., Ordi-Ros J., Derksen R.H., Machin S.J., Barquinero J., et al. The " Primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989, 68:366-374.
2. Cabral A.R., Cabiedes J., Alarcon-Segovia D. Antibodies to phospholipid-free beta 2-glycoprotein-i in patients with primary antiphospholipid syndrome. J Rheumatol 1995, 22:1894-1898.
3. Asherson R.A. A " Primary" antiphospholipid syndrome?. J Rheumatol 1988, 15:1742-1746.
4. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002, 46:1019-1027.
5. Bramham K, Hunt BJ, Germain S, Calatayud I, Khamashta M, Bewley S, et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010;19:58-64.
6. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010;376:1498-509.
7. Giannakopoulos B., Passam F., Rahgozar S., Krilis S.A. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007, 109:422-430.
8. Ma K., Simantov R., Zhang J.C., Silverstein R., Hajjar K.A., McCrae K.R. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000, 275:15541-15548.
9. Zhang J., McCrae K.R. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 2005, 105:1964-1969.
10. Pierangeli S.S., Vega-Ostertag M.E., Raschi E., Liu X., Romay-Penabad Z., De Micheli V., et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007, 66:1327-1333.
11. Dunoyer-Geindre S., de Moerloose P., Galve-de Rochemonteix B., Reber G., Kruithof E.K. Nfkappab is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost 2002, 88:851-857.
12. Bohgaki M., Atsumi T., Yamashita Y., Yasuda S., Sakai Y., Furusaki A., et al. The p38 mitogen-activated protein kinase (mapk) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2glycoprotein I antibodies. Int Immunol 2004, 16:1633-1641.
13. Vega-Ostertag M., Casper K., Swerlick R., Ferrara D., Harris E.N., Pierangeli S.S. Involvement of p38 mapk in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005, 52:1545-1554.
14. Simoncini S., Sapet C., Camoin-Jau L., Bardin N., Harle J.R., Sampol J., et al. Role of reactive oxygen species and p38 mapk in the induction of the proadhesive endothelial state mediated by IGG from patients with antiphospholipid syndrome. Int Immunol 2005, 17:489-500.
15. Montiel-Manzano G., Romay-Penabad Z., Papalardo de Martinez E., Meillon-Garcia L.A., Garcia-Latorre E., Reyes-Maldonado E., et al. In vivo effects of an inhibitor of nuclear factor-kappa b on thrombogenic properties of antiphospholipid antibodies. Ann N Y Acad Sci 2007, 1108:540-553.
16. Shi T., Giannakopoulos B., Yan X., Yu P., Berndt M.C., Andrews R.K., et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein IB-IX-V. Arthritis Rheum 2006, 54:2558-2567.
17. Lellouche F., Martinuzzo M., Said P., Maclouf J., Carreras L.O. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991, 78:2894-2899.
18. Hulstein J.J., Lenting P.J., de Laat B., Derksen R.H., Fijnheer R., de Groot P.G. Beta2-glycoprotein I inhibits von willebrand factor dependent platelet adhesion and aggregation. Blood 2007, 110:1483-1491.
19. Cariou R., Tobelem G., Soria C., Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med 1986, 314:1193-1194.
20. Galli M., Willems G.M., Rosing J., Janssen R.M., Govers-Riemslag J.W., Comfurius P., et al. Antiprothrombin IGG from patients with antiphospholipid antibodies inhibits the inactivation of factor VA by activated protein C. Br J Haematol 2005, 129:240-247.
21. Le Thi Huong D., Wechsler B., Piette J.C. Pregnancy and systemic lupus erythematosus. Rev Med Interne 2008, 29:725-730.
22. Ames P.R., Tommasino C., Iannaccone L., Brillante M., Cimino R., Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - a crucial role for acquired free protein S deficiency. Thromb Haemost 1996, 76:190-194.
23. Devreese KM, Hoylaerts MF. Is there an association between complement activation and antiphospholipid antibody-related thrombosis? Thromb Haemost 2010;104:1279-81.
24. Pierangeli S.S., Vega-Ostertag M., Liu X., Girardi G. Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome. Ann N Y Acad Sci 2005, 1051:413-420.
25. Fischetti F., Durigutto P., Pellis V., Debeus A., Macor P., Bulla R., et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005, 106:2340-2346.
26. Shinzato M.M., Bueno C., Trindade Viana V.S., Borba E.F., Goncalves C.R., Bonfa E. Complement-fixing activity of anticardiolipin antibodies in patients with and without thrombosis. Lupus 2005, 14:953-958.
27. Romay-Penabad Z., Liu X.X., Montiel-Manzano G., Papalardo De Martinez E., Pierangeli S.S. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann N Y Acad Sci 2007, 1108:554-566.
28. Peerschke E.I., Yin W., Alpert D.R., Roubey R.A., Salmon J.E., Ghebrehiwet B. Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus 2009, 18:530-538.
29. Holers V.M., Girardi G., Mo L., Guthridge J.M., Molina H., Pierangeli S.S., et al. Complement c3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002, 195:211-220.
30. Redecha P., Tilley R., Tencati M., Salmon J.E., Kirchhofer D., Mackman N., et al. Tissue factor: a link between c5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007, 110:2423-2431.
31. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10:1222-1226.
32. Oku K., Atsumi T., Bohgaki M., Amengual O., Kataoka H., Horita T., et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009, 68:1030-1035.
33. Francis J., Rai R., Sebire N.J., El-Gaddal S., Fernandes M.S., Jindal P., et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Mol Hum Reprod 2006, 12:435-442.
34. Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007;196:167e1-5.
35. Pierangeli S.S., Girardi G., Vega-Ostertag M., Liu X., Espinola R.G., Salmon J. Requirement of activation of complement c3 and c5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005, 52:2120-2124.
36. Carrera-Marin A.L., Romay-Penabad Z., Qu H., Papalardo E., Lambris J., Reyes-Maldonado E., et al. A c5a receptor antagonist ameliorates in vivo effects of antiphospholipid antibodies. Arthritis Rheum 2009, 60:s767.
37. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
38. McIntyre J.A., Wagenknecht D.R. Antiphosphatidylethanolamine (ape) antibodies: a survey. J Autoimmun 2000, 15:185-193.
39. Szodoray P., Tarr T., Tumpek J., Kappelmayer J., Lakos G., Poor G., et al. Identification of rare antiphospholipid/protein cofactor autoantibodies in patients with systemic lupus erythematosus. Autoimmunity 2009, 42:497-506.
40. Shen Y.M., Lee R., Frenkel E., Sarode R. Iga antiphospholipid antibodies are an independent risk factor for thromboses. Lupus 2008, 17:996-1003.
41. Sweiss NJ, Bo R, Kapadia R, Manst D, Mahmood F, Adhikari T, et al. Iga anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS One 2010;5.
42. Mehrani T, Petri M. Association of iga anti-{beta}2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus. J Rheumatol 2010.
43. Rai R., Cohen H., Dave M., Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997, 314:253-257.
44. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996, 174:1584-1589.
45. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005:CD002859.
46. Laskin C.A., Spitzer K.A., Clark C.A., Crowther M.R., Ginsberg J.S., Hawker G.A., et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled hepasa trial. J Rheumatol 2009, 36:279-287.
47. Farquharson R.G., Quenby S., Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002, 100:408-413.
48. Noble L.S., Kutteh W.H., Lashey N., Franklin R.D., Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005, 83:684-690.
49. Stephenson M.D., Ballem P.J., Tsang P., Purkiss S., Ensworth S., Houlihan E., et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004, 26:729-734.
50. Silver R.K., MacGregor S.N., Sholl J.S., Hobart J.M., Neerhof M.G., Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993, 169:1411-1417.
51. Cowchock F.S., Reece E.A., Balaban D., Branch D.W., Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992, 166:1318-1323.
52. Triolo G., Ferrante A., Ciccia F., Accardo-Palumbo A., Perino A., Castelli A., et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003, 48:728-731.
53. Branch D.W., Peaceman A.M., Druzin M., Silver R.K., El-Sayed Y., Silver R.M., et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 2000, 182:122-127.
54. Vaquero E., Lazzarin N., Valensise H., Menghini S., Di Pierro G., Cesa F., et al. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin. Am J Reprod Immunol 2001, 45:174-179.
55. Clark C.A., Spitzer K.A., Crowther M.A., Nadler J.N., Laskin M.D., Waks J.A., et al. Incidence of post-partum thrombosis and preterm delivery in women with antiphospholipid antibodies and recurrent pregnancy loss. J Rheumatol 2007, 34:992-996.
56. Le Thi Huong D., Wechsler B., Vauthier-Brouzes D., Duhaut P., Costedoat N., Andreu M.R., et al. The second trimester doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford) 2006, 45:332-338.
57. Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003, 101:1827-1832.
58. Opatrny L., David M., Kahn S.R., Shrier I., Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without auto-immune disease: a metaanalysis. J Rheumatol 2006, 33:2214-2221.
59. Galli M., Luciani D., Bertolini G., Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003, 102:2717-2723.
60. Urbanus R.T., Siegerink B., Roest M., Rosendaal F.R., de Groot P.G., Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the ratio study: a case-control study. Lancet Neurol 2009, 8:998-1005.
61. Forastiero R., Martinuzzo M., Pombo G., Puente D., Rossi A., Celebrin L., et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005, 3:1231-1238.
62. Pengo V., Biasiolo A., Pegoraro C., Cucchini U., Noventa F., Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005, 93:1147-1152.
63. Ruffatti A., Tonello M., Del Ross T., Cavazzana A., Grava C., Noventa F., et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006, 96:337-341.